Anti-hepatitis Screening Library
Hepatitis virus infection is a serious public health problem and the cost of treating chronic hepatitis is quite expensive. Hepatitis B and C cause up to 80% of liver cancer deaths and hepatitis C virus (HCV) has become the leading cause of liver-related morbidity and mortality worldwide. HCV is known as one of the most dangerous diseases. In recent years, vaccines against hepatitis A and B and the use of various antiviral drugs have been effective in controlling hepatitis virus infection. However, these drugs have also led to the emergence of hepatitis C virus variants. To date, there is still no vaccine that can protect viral hepatitis C. In addition, currently available direct-acting antiviral drugs (DAAs) against HCV are ineffective against all genotypic variants of the virus, and the resistance against drugs in clinical use will eventually emerge. Researchers worldwide are therefore searching for antiviral drugs with new structures and mechanisms of action in hepatitis C.
BOC Sciences has designed its anti-HCV library containing more than 1,600 compounds.
Figure 1. High-throughput screens to identify compounds that inhibit HBV. (Xia, Y.; Liang, T. J. 2018)
Anti-hepatitis Screening Library Design
- BOC Sciences supports advanced 2D fingerprint similarity search
- Our library is capable of providing biologically active compounds with IC50, Ki, etc. <=10 μM, inhibition >25%
- We search for small molecules similar to compounds from the reference database using MDL public key and Tanimoto similarity cut-off of 85% to obtain drug-like screening compounds of potential hepatitis C virus inhibitors
- In addition, small subsets are prepared against Hepatitis A and B viruses based on a reference database of about 3,000 bioactive compounds with confirmed potency in HCV assays
All compounds show desired activity against the following Hepatitis C virus genotypes and their targets:
- Hepatitis C virus
- NS3/NS4A serine protease
- Hepatitis C virus genotype 1a (isolate 1)
- RNA-directed RNA polymerase
- Hepatitis C virus genotype 1b (isolate BK)
- NS5B RNA-dependent RNA polymerase
- NS3 protease/helicase
- Genome polyprotein
Anti-hepatitis Screening Library Characteristics
- No PAINS or toxic substances/unwanted functions: filtered by strict ‘Ro5-like’ physicochemical and most stringent in-house structural filters
- Bioactivity and safety confirmed by preclinical studies and clinical trials
- Structural diversity, medicinal activity, and cellular penetration
- Structural document, IC50, and other chemical and biological data are provided
- All compounds are continually updated
- All of these compounds with Tanimoto index ≥ 0.85
- Compound cherry-picking service is provided
What We Deliver
- Delivered within 2 weeks in any customer-preferred format
- Powders, dry films or DMSO solutions formatted in vials, 96 or 384-well plates
- All compounds have a minimum purity of 90% assessed by 1H NMR and HPLC
- Analytical data is provided
BOC Sciences provides professional, rapid and high-quality services of Anti-hepatitis Screening Library design at competitive prices for global customers. Personalized and customized services of Anti-hepatitis Screening Library design can satisfy any innovative scientific study demands. Our clients have direct access to our staff and prompt feedback to their inquiries. If you are interested in our services, please contact us immediately!
Reference
- Xia, Y.; Liang, T. J. Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of HBV Infection. Gastroenterology. 2018. 156(2).
